• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Rite Aid Corporation

    10/12/23 5:27:02 PM ET
    $RAD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $RAD alert in real time by email
    NT 10-Q 1 tm2328368d1_nt10q.htm NT 10-Q

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    SEC File Number: 001-05742

    CUSIP Number: 767754872

     

    NOTIFICATION OF LATE FILING

     

    (Check One)  ☐  Form 10-K  ☐  Form 20-F  ☐  Form 11-K x  Form 10-Q  ☐  Form 10-D  ☐   Form N-CEN  ☐  Form N-CSR
       
      For Period Ended: September 2, 2023
       
      ☐  Transition Report on Form 10-K
      ☐  Transition Report on Form 20-F
      ☐  Transition Report on Form 11-K
      ☐  Transition Report on Form 10-Q
       
      For the Transition Period Ended:
       

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A

     

    Part I — Registrant Information

     

    Rite Aid Corporation

    Full Name of Registrant

     

     

    Former Name if Applicable

     

    P.O. Box 3165

    Harrisburg, Pennsylvania 17105

    United States

    Address of Principal Executive Office

     

    Part II — Rules 12b-25(b) and (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

        (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
      x  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
        (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

     

     

    Part III — Narrative

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Rite Aid Corporation (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the quarter ended September 2, 2023 (the “Form 10-Q”) by the prescribed due date for the reasons further described below.

     

    As previously disclosed by the Company, including in its Quarterly Report on Form 10-Q for the quarter ended June 3, 2023, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 11, 2023, the Company has been engaged in reviewing and continues to review strategic alternatives to recapitalize, refinance or otherwise optimize its capital structure (the “Ongoing Review”), which may ultimately result in the Company pursuing one or more significant corporate transactions or other remedial measures. As part of the preparation of the Form 10-Q, the Company is conducting an impairment charge analysis, which, together with the processes involved in the Ongoing Review, require significant resources from the Company's financial, accounting and administrative personnel. As a result, the Company is unable to complete and file the Form 10-Q by the prescribed due date without unreasonable effort and expense.

     

    The Company is working diligently to complete its financial statements and related disclosures and anticipates that the Form 10-Q will be filed on or before October 17, 2023, as permitted by Rule 12b-25 promulgated under the Securities Exchange Act of 1934, as amended.

     

    Part IV — Other Information

     

    (1) Name and telephone number of person to contact in regard to this notification.

     

      Matthew C. Schroeder   (717) 761-2633
      (Name)   (Telephone Number)

     

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     

    x  Yes ☐  No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒  Yes  ☐  No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    When the Company completes the preparation of the 10-Q, including the ongoing impairment charge analysis, discussed in Part III above, the Company expects to report a significant increase in net loss for the quarter ended September 2, 2023, as compared to the corresponding quarter ended August 27, 2022. Such increase would result in part from the increase in impairment charges, litigation charges and higher professional expenses. Additionally, the Company expects to also report a significant increase in its outstanding debt for the quarter ended September 2, 2023, as compared to the corresponding quarter ended August 27, 2022.

     

    Forward-Looking Statements

     

    Statements in this notification that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company’s expectations concerning the timing of completing the Ongoing Review, including the ongoing impairment charge analysis; the outcome of the Ongoing Review and the impact of such review on the Company’s financial statements; the timing of the filing of the Form 10-Q; and any assumptions underlying any of the foregoing. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “should,” and “will” and variations of such words and similar expressions are intended to identify such forward-looking statements.

     

    These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties. These risks, assumptions and uncertainties are more fully described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and in other documents that we file or furnish with the SEC which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to rely on these forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any current intention, and assumes no duty, to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

     

     

     

     

    Rite Aid Corporation

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: October 12, 2023 By: /s/ Matthew C. Schroeder
       

    Matthew C. Schroeder

    Executive Vice President and Chief Financial Officer

     

     

     

     

    Get the next $RAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RAD

    DatePrice TargetRatingAnalyst
    4/7/2022$16.00 → $1.00Hold → Sell
    Deutsche Bank
    6/25/2021$21.00 → $12.00Neutral → Underweight
    JP Morgan
    More analyst ratings

    $RAD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Carenet Health Acquiring Health Dialog, Enhancing Clinical Team and Advancing Insights-Driven Platform Dedicated to the Business of Healthcare

      Expanded personalized population health capabilities support better health journeys for patients Carenet Health, a trusted partner in helping organizations simplify and power the business of healthcare, is excited to announce it is acquiring Health Dialog, a worldwide leader in delivering clinical decision support offerings. This acquisition enables Carenet to leverage its combined platform, analytics and clinicians to deliver greater efficiency and outcomes-based financial performance for clients. Health Dialog provides personalized population health services to health plans, providers, employers and pharmaceutical manufacturers. Carenet is acquiring all assets of Health Dialog from

      3/6/24 11:05:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Receives Court Approval of "First Day" Motions to Support Business Operations

      Secures Interim Approval to Access Up to $3.45 Billion in Debtor-in-Possession Financing Continues to Serve Customers and Deliver Healthcare Products and Services Across Retail and Online Platforms Rite Aid Corporation (OTC:RADCQ) ("Rite Aid" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of New Jersey for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on October 15, 2023. The Court granted interim approval to access up to $3.45 billion in debtor-in-possession financing from certain of its lenders. This financing is expected to provide sufficient liquidity to support the Company th

      10/17/23 11:05:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation Appoints Jeffrey S. Stein Chief Executive Officer

      Stein Succeeds Elizabeth "Busy" Burr Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced that its Board of Directors has appointed Jeffrey S. Stein as Chief Executive Officer (CEO), Chief Restructuring Officer (CRO) and a member of the Board of Directors, effective immediately. Mr. Stein succeeds Elizabeth ("Busy") Burr, who has served as Interim CEO of Rite Aid since January 2023. Ms. Burr will continue to serve on the Company's Board. Mr. Stein brings more than three decades of experience as a leader and executive director at both public and private companies. Mr. Stein has particular expertise in supporting companies that are driving meaningful business tran

      10/15/23 10:37:00 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Rite Aid Corporation (Amendment)

      SC 13G/A - RITE AID CORP (0000084129) (Subject)

      2/9/23 11:32:52 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Rite Aid Corporation (Amendment)

      SC 13G/A - RITE AID CORP (0000084129) (Subject)

      7/11/22 1:13:14 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Rite Aid Corporation (Amendment)

      SC 13G/A - RITE AID CORP (0000084129) (Subject)

      3/9/22 8:44:09 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rite Aid downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Rite Aid from Hold to Sell and set a new price target of $1.00 from $16.00 previously

      4/7/22 7:32:45 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid downgraded by JP Morgan with a new price target

      JP Morgan downgraded Rite Aid from Neutral to Underweight and set a new price target of $12.00 from $21.00 previously

      6/25/21 7:27:02 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Deutsche Bank reiterated coverage on Rite Aid with a new price target

      Deutsche Bank reiterated coverage of Rite Aid with a rating of Hold and set a new price target of $27.00 from $17.00 previously

      3/25/21 9:26:08 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Leadership Updates

    Live Leadership Updates

    See more
    • Rite Aid Corporation Appoints Jeffrey S. Stein Chief Executive Officer

      Stein Succeeds Elizabeth "Busy" Burr Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced that its Board of Directors has appointed Jeffrey S. Stein as Chief Executive Officer (CEO), Chief Restructuring Officer (CRO) and a member of the Board of Directors, effective immediately. Mr. Stein succeeds Elizabeth ("Busy") Burr, who has served as Interim CEO of Rite Aid since January 2023. Ms. Burr will continue to serve on the Company's Board. Mr. Stein brings more than three decades of experience as a leader and executive director at both public and private companies. Mr. Stein has particular expertise in supporting companies that are driving meaningful business tran

      10/15/23 10:37:00 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Takes Steps to Accelerate Transformation and Position Company for Long-Term Success

      Reaches Agreement in Principle with Key Creditors on the Terms of Financial Restructuring Plan Initiates Voluntary Chapter 11 Process to Implement a Consensual Financial Restructuring That Will Significantly Reduce Debt and Enable Execution of Key Initiatives Receives Commitment for $3.45 Billion in New Financing to Support Business Operations Continuing to Serve Customers and Deliver Healthcare Products and Services Across Retail and Online Platforms Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced it has reached an agreement in principle with certain of its senior secured noteholders on the terms of a financial restructuring plan that will allow the Co

      10/15/23 10:37:00 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Rite Aid Corporation

      NT 10-Q - RITE AID CORP (0000084129) (Filer)

      1/12/24 5:00:11 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits

      8-K - RITE AID CORP (0000084129) (Filer)

      12/27/23 6:03:09 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - RITE AID CORP (0000084129) (Filer)

      11/1/23 4:30:23 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Dupaul Christopher W. claimed ownership of 34,525 shares

      3 - RITE AID CORP (0000084129) (Issuer)

      8/24/23 4:33:34 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Schroeder Matt

      4 - RITE AID CORP (0000084129) (Issuer)

      7/28/23 4:10:16 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Mennen Justin L.

      4 - RITE AID CORP (0000084129) (Issuer)

      7/28/23 4:09:48 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Financials

    Live finance-specific insights

    See more
    • Rite Aid Corporation Reports Fiscal 2024 First Quarter Results

      Revenues of $5.7 Billion, Compared to Prior Year Revenues of $6.0 Billion Retail Comparable Same Store Prescriptions Increased 4.7 Percent – Comparable Same Store Prescriptions, Excluding COVID Impact, Increased 7.4 Percent Net Loss of $306.7 Million Compared to Prior Year Net Loss of $110.2 Million – Increase Largely Attributable to a Goodwill Impairment Charge at Elixir Adjusted EBITDA of $91.7 Million, Compared to Prior Year Adjusted EBITDA of $100.1 Million Updates Fiscal 2024 Outlook Rite Aid Corporation (NYSE:RAD) today reported operating results for its first fiscal quarter ended June 3, 2023. "Our first quarter results were driven by strong script growth, solid ph

      6/29/23 7:00:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid to Release First Quarter Results on June 29

      Rite Aid Corporation (NYSE:RAD) will release financial results for its Fiscal 2024 First Quarter, which ended June 3, 2023, on Thursday, June 29, 2023. The company will hold an analyst call at 8:30 a.m. ET with remarks by Rite Aid's management team. The call will be broadcast at https://investors.riteaid.com. The telephone replay will be available beginning at 12:00 p.m. ET on Thursday, June 29, 2023, through 11:59 p.m. ET on July 29, 2023. To access the replay of the call, please dial (800) 770-2030 or (647) 362-9199 and enter the seven-digit reservation number 9029129. The webcast replay of the call will also be available at https://investors.riteaid.com starting at 12 p.m. ET Thursda

      6/12/23 8:30:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation Reports Fiscal 2023 Fourth Quarter and Full Year Results and Provides Fiscal 2024 Outlook

      Fourth Quarter Highlights: Revenues of $6.1 billion, Comparable to Prior Year Retail Comparable Same Store Prescriptions Increased 5.2 Percent – Comparable Same Store Prescriptions, Excluding COVID Impacts, Increased 9.7 Percent Net Loss per Share of $4.39, Compared to Prior Year Net Loss per Share of $7.18 Adjusted EBITDA of $128.6 million, Compared to the Prior Year Adjusted EBITDA of $106.1 million Completed Tender Offer for $165 million of our 2025 notes – Reducing Amount Outstanding to $320 million From $600 million at Beginning of Fiscal 2022 Full Year Highlights: Revenues of $24.1 billion, Compared to Prior Year Revenues of $24.6 billion Retail Comparable Same

      4/20/23 7:00:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples